Cargando…

Early immune modulation by single-agent trastuzumab as a marker of trastuzumab benefit

BACKGROUND: Optimising the selection of HER2-targeted regimens by identifying subsets of HER2-positive breast cancer (BC) patients who need more or less therapy remains challenging. We analysed BC samples before and after treatment with 1 cycle of trastuzumab according to the response to trastuzumab...

Descripción completa

Detalles Bibliográficos
Autores principales:	Triulzi, Tiziana, Regondi, Viola, De Cecco, Loris, Cappelletti, Maria Rosa, Di Modica, Martina, Paolini, Biagio, Lollini, Pier Luigi, Di Cosimo, Serena, Sfondrini, Lucia, Generali, Daniele, Tagliabue, Elda
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group UK 2018
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6288086/ https://www.ncbi.nlm.nih.gov/pubmed/30478407 http://dx.doi.org/10.1038/s41416-018-0318-0

Ejemplares similares

HER2 mRNA Levels, Estrogen Receptor Activity and Susceptibility to Trastuzumab in Primary Breast Cancer
por: Triulzi, Tiziana, et al.
Publicado: (2022)

HER2 signaling regulates the tumor immune microenvironment and trastuzumab efficacy
por: Triulzi, Tiziana, et al.
Publicado: (2018)

Taxanes enhance trastuzumab-mediated ADCC on tumor cells through NKG2D-mediated NK cell recognition
por: Di Modica, Martina, et al.
Publicado: (2015)

Extracellular Matrix Features Discriminate Aggressive HER2-Positive Breast Cancer Patients Who Benefit from Trastuzumab Treatment
por: Rybinska, Ilona, et al.
Publicado: (2020)

Whole-transcriptome analysis links trastuzumab sensitivity of breast tumors to both HER2 dependence and immune cell infiltration
por: Triulzi, Tiziana, et al.
Publicado: (2015)

Infrared Spectroscopic Imaging Visualizes a Prognostic Extracellular Matrix-Related Signature in Breast Cancer
por: Tiwari, Saumya, et al.
Publicado: (2020)

The Link Between the Microbiota and HER2+ Breast Cancer: The New Challenge of Precision Medicine
por: Di Modica, Martina, et al.
Publicado: (2022)

Predicting the Efficacy of HER2-Targeted Therapies: A Look at the Host
por: Di Modica, Martina, et al.
Publicado: (2017)

The Emerging Role of the Microbiota in Breast Cancer Progression
por: Bernardo, Giancarla, et al.
Publicado: (2023)

Local Administration of Caloric Restriction Mimetics to Promote the Immune Control of Lung Metastases
por: Le Noci, Valentino, et al.
Publicado: (2019)

The Educational Program of Macrophages toward a Hyperprogressive Disease-Related Phenotype Is Orchestrated by Tumor-Derived Extracellular Vesicles
por: Indino, Serena, et al.
Publicado: (2022)

Trastuzumab cardiotoxiciy: the age-old balance of risk and benefit
por: Ewer, Michael S, et al.
Publicado: (2016)

Resistance to Trastuzumab
por: Vivekanandhan, Sneha, et al.
Publicado: (2022)

ADAM10 mediates trastuzumab resistance and is correlated with survival in HER2 positive breast cancer
por: Feldinger, Katharina, et al.
Publicado: (2014)

Trastuzumab-induced thrombocytopenia after eight cycles of trastuzumab treatment
por: Zhou, Qiong, et al.
Publicado: (2020)

MiR-205 as predictive biomarker and adjuvant therapeutic tool in combination with trastuzumab
por: Cataldo, Alessandra, et al.
Publicado: (2018)

Nuclear HER4 mediates acquired resistance to trastuzumab and is associated with poor outcome in HER2 positive breast cancer
por: Nafi, Siti Norasikin Mohd, et al.
Publicado: (2014)

Intravenous and subcutaneous formulations of trastuzumab, and trastuzumab biosimilars: implications for clinical practice
por: Waller, Cornelius F., et al.
Publicado: (2021)

Immune Effects of Trastuzumab
por: Nuti, Marianna, et al.
Publicado: (2011)

Anti-tumor effects of retinoids combined with trastuzumab or tamoxifen in breast cancer cells: induction of apoptosis by retinoid/trastuzumab combinations
por: Koay, Debbie C, et al.
Publicado: (2010)

Wound Healing Fluid Reflects the Inflammatory Nature and Aggressiveness of Breast Tumors
por: Agresti, Roberto, et al.
Publicado: (2019)

Tumor Extracellular Matrix Remodeling: New Perspectives as a Circulating Tool in the Diagnosis and Prognosis of Solid Tumors
por: Giussani, Marta, et al.
Publicado: (2019)

Cancer-Associated Adipocytes in Breast Cancer: Causes and Consequences
por: Rybinska, Ilona, et al.
Publicado: (2021)

Prospective neoadjuvant analysis of PET imaging and mechanisms of resistance to Trastuzumab shows role of HIF1 and autophagy
por: Koukourakis, M I, et al.
Publicado: (2014)

Cardiac management during adjuvant trastuzumab therapy: recommendations of the Canadian Trastuzumab Working Group
por: Mackey, J.R., et al.
Publicado: (2008)

Effect of Trastuzumab–HER2 Complex Formation on Stress-Induced Modifications in the CDRs of Trastuzumab
por: Spanov, Baubek, et al.
Publicado: (2022)

NSABP FB-7: a phase II randomized neoadjuvant trial with paclitaxel + trastuzumab and/or neratinib followed by chemotherapy and postoperative trastuzumab in HER2(+) breast cancer
por: Jacobs, Samuel A., et al.
Publicado: (2019)

Trastuzumab: a cardiologist’s perspective
por: Côté, Marc André
Publicado: (2008)

Target Points in Trastuzumab Resistance
por: Shojaei, Sahar, et al.
Publicado: (2012)

Psoriasis Induced by Trastuzumab (Herceptin®)
por: Kim, Dae Hun, et al.
Publicado: (2013)

Trastuzumab deruxtecan for breast cancer
Publicado: (2022)

Trastuzumab-Induced Interstitial Pneumonitis
por: Errisuriz, Kimberly, et al.
Publicado: (2023)

Trastuzumab and ECG Changes Dilemma
por: Alizadehasl, Azin, et al.
Publicado: (2023)

Targeting of preexisting and induced breast cancer stem cells with trastuzumab and trastuzumab emtansine (T-DM1)
por: Diessner, J, et al.
Publicado: (2014)

A Case of Trastuzumab-Associated Cardiomyopathy Presenting as an Acute Coronary Syndrome: Acute Trastuzumab Cardiotoxicity
por: Hidalgo, Sylvana, et al.
Publicado: (2013)

Correction to: NSABP FB-7: a phase II randomized neoadjuvant trial with paclitaxel + trastuzumab and/or neratinib followed by chemotherapy and postoperative trastuzumab in HER2+ breast cancer
por: Jacobs, Samuel A., et al.
Publicado: (2020)

Somatic Mutation Profiling and Associations With Prognosis and Trastuzumab Benefit in Early Breast Cancer
por: Loi, Sherene, et al.
Publicado: (2013)

Outcomes of HER2-positive early breast cancer patients in the pre-trastuzumab and trastuzumab eras: a real-world multicenter observational analysis. The RETROHER study
por: Vici, Patrizia, et al.
Publicado: (2014)

ELISA assay employing epitope-specific monoclonal antibodies to quantify circulating HER2 with potential application in monitoring cancer patients undergoing therapy with trastuzumab
por: Agnolon, Valentina, et al.
Publicado: (2020)

Cost-effectiveness analysis of trastuzumab deruxtecan versus trastuzumab emtansine for HER2-positive breast cancer
por: Yang, Jiangping, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_r66t1lr94a3g49m3o8khg07e2n